Bone metastases are a common and debilitating manifestation of advanced cancer, often leading to pain, pathological fractures, spinal cord compression, and impaired mobility. Traditionally managed with palliative radiotherapy to alleviate symptoms, the treatment paradigm is shifting as improvements in systemic therapies have extended patient survival. There is now a growing emphasis on achieving durable local control of metastatic lesions, especially in patients with oligometastatic disease, characterized by a limited number of metastases. Stereotactic body radiotherapy (SBRT) has emerged as a highly precise and effective modality, delivering high-dose radiation to targeted sites while sparing healthy tissue. Clinical trials have demonstrated their potential in improving progression-free and overall survival, particularly in carefully selected patients. Recent studies have explored prophylactic radiotherapy in high-risk asymptomatic bone metastases, showing promising results in reducing skeletal-related events and correlating with improved survival. Furthermore, the development of refined classifications for oligometastatic disease has enhanced the ability to tailor treatment strategies. Beyond local control, SBRT may enhance systemic immune responses, potentially synergizing with immunotherapies. As evidence grows, SBRT is increasingly integrated into multidisciplinary care for both oligometastatic and polymetastatic patients. This chapter reviews the evolution of radiotherapy in bone metastases, emphasizing the expanding role of SBRT, current clinical evidence, patient selection, and future directions for personalized oncologic care.